Switzerland Patent System

The Swiss IP Box allows companies to reduce cantonal and communal tax on income derived from qualifying IP. Qualifying IP assets include: patents (Swiss national patents and EP patents validated in Switzerland); supplementary protection certificates (SPCs) for pharmaceutical and plant protection products; comparable foreign equivalent rights. Importantly, the Swiss IP Box does NOT cover all IP — trademarks, copyrights, know-how, and trade secrets do NOT qualify. Only patent income qualifies. Qualifying income includes: licensing fees and royalties from qualified IP; capital gains from the sale of qualified IP; income from manufacturing products that embed a qualified patent (if the IP contribution can be quantified).

The OECD nexus approach requires that the IP Box benefit be proportional to qualifying R&D expenditure incurred in Switzerland. The modified nexus ratio = (Swiss R&D expenditure + outsourced non-group R&D) / (total R&D expenditure including acquired IP and group R&D). Cantons can set their IP Box deduction up to 90% of qualifying income — effectively reducing the cantonal tax rate on IP income to a maximum of 10% of the standard cantonal rate. For cantons with standard rates around 12–15%, this means IP income faces a maximum 1.2–1.5% cantonal IP Box rate. Combined federal + cantonal effective tax rates on IP Box income range from approximately 7.5% to 10% depending on canton, vs. standard Swiss corporate rates of 12–21% (depending on canton). Zug, Nidwalden, and Schwyz offer the lowest overall effective tax rates for IP holding companies in Switzerland.

The critical constraint on Swiss IP Box planning: the nexus approach requires that IP Box benefits be proportional to qualifying R&D actually performed in Switzerland (or contracted to unrelated third parties). Acquiring an existing patent portfolio from a related party and holding it in Switzerland without performing qualifying R&D does not give full IP Box benefit. A company using a Swiss IP Box must have genuine R&D activity in Switzerland — employed researchers, R&D-focused employees, laboratory or technology development operations — proportional to the IP income it claims. This rules out pure 'brass plate' IP holding companies that simply move patents to Switzerland for the tax rate without substance. Compare with Ireland's knowledge development box (6.25%) and Netherlands Innovation Box (9%), which have similar nexus requirements under BEPS Action Plan 5.

Switzerland has its own SPC (Ergänzendes Schutzzertifikat / Certificat complémentaire de protection) regime under the Swiss Federal Patent Act (Art. 140a–140q PatG), separate from the EU SPC Regulation (Regulation 469/2009). A Swiss SPC extends the effective term of a patent covering a pharmaceutical or plant protection product by the time lost during regulatory approval, minus 5 years. Maximum Swiss SPC extension: 5 years (same as EU SPC maximum). Switzerland's SPC term may differ from EU member state SPCs because the regulatory approval date is based on the Swiss authorization by Swissmedic (the Swiss drug regulatory authority) rather than EMA marketing authorization. Swissmedic sometimes grants authorization before the EMA, sometimes after. Companies launching drugs in Switzerland must calculate Swiss SPC terms separately from EU SPCs.

Switzerland, as an EPC contracting state, applies Article 54 EPC for novelty — absolute novelty is required. Any public disclosure of the invention before the Swiss or EP filing date is prior art, regardless of who made the disclosure. The applicant's own prior publications, conference presentations, product demonstrations, and patent applications are prior art. There is a very narrow exception under Article 55 EPC for disclosures at officially recognized international exhibitions (listed under the Convention on International Exhibitions), but this does NOT apply to ordinary scientific publications, trade shows, investor pitches, or product launches. US inventors planning Swiss/European patent protection must file before any public disclosure — the 12-month US grace period under AIA § 102(b)(1) does NOT protect against the Swiss disclosure being prior art under EPC.

Switzerland follows EPC Article 52(2)(c) — programs for computers are excluded from patentability 'as such.' IPI and Swiss courts apply the same 'technical character' approach as the EPO. Software that achieves a technical effect — controlling a technical process, improving a computer system's technical performance, solving a technical problem — can be patented in Switzerland through an EP patent validated at IPI. The EPO's software patent approach is more permissive than the post-Alice USPTO standard. Swiss precision engineering and automation software patents are well-established — CNC machine control, robotics programming, medical device embedded software, and industrial IoT systems have all obtained patent protection through the EPO/Swiss route.

Swiss-type claims (also known as 'Swiss form' claims) were developed by the EPO specifically to allow second medical use patents that would otherwise be excluded as method-of-treatment claims. The Swiss-type claim format is: 'Use of substance X for the manufacture of a medicament for the treatment of disease Y.' Swiss-type claims have been replaced at the EPO by purpose-limited product claims under the EPC 2000 rules ('Substance X for use in the treatment of Y'). For applications at the EPO filed after April 2010, purpose-limited product claims are the preferred format. However, Swiss-type claims filed before that date remain valid until expiry. For IPI national applications, Swiss patent law permits both Swiss-type claims and purpose-limited product claims for second medical use.

Switzerland has a broad research exemption in patent law (Art. 9 PatG). The Swiss research exemption permits using a patented invention for scientific research purposes without the patent holder's permission — broader than the US experimental use exception (which is extremely narrow under Madey v. Duke University, 307 F.3d 1351 (Fed. Cir. 2002)). The Swiss research exemption is significant for ETH Zurich, EPFL, and university research that builds on commercial technology. The exemption applies to genuine scientific research; commercial development using a patented compound or device (e.g., clinical trials for a drug) is not automatically exempt, but Switzerland has a Bolar exemption (Art. 9a PatG) specifically for regulatory submissions — allowing generic manufacturers to use patented drugs to prepare applications for Swiss marketing authorization before patent expiry.

Switzerland is excluded from the Unitary Patent and Unified Patent Court (UPC) because Switzerland is not a member of the European Union. The Unitary Patent and UPC are EU institutions — only EU member states can participate. Switzerland has rejected EU membership in multiple referendums and operates under a complex set of bilateral agreements with the EU. As a result, even though Switzerland is a contracting state of the European Patent Convention (EPC) and full member of the EPO, it cannot participate in the Unitary Patent system or the UPC that entered into force June 1, 2023. The practical consequence: for every EP patent you want to be effective in Switzerland, you must nationally validate the EP patent at IPI (Institut Fédéral de la Propriété Intellectuelle) in Berne after EPO grant. The Unitary Patent (which can cover France, Germany, Italy, the Netherlands, Spain, and 15+ other EU states with a single registration) does NOT extend to Switzerland. Companies seeking European coverage including Switzerland — which is critical for the Swiss pharma, medtech, and precision engineering sectors — must budget for Swiss national EP validation as a separate cost on top of Unitary Patent costs.

The Swiss IP Box is a cantonal tax incentive that allows companies to pay a reduced tax rate (effectively up to 10% cantonal tax) on income derived from qualifying intellectual property — specifically patents and supplementary protection certificates (SPCs). Here's how it works: (1) Qualifying IP: patents (Swiss national patents and EP patents validated in Switzerland) and SPCs. Not all IP qualifies — trademarks, copyrights, know-how, and trade secrets do NOT qualify for the Swiss IP Box; (2) Qualifying income: royalties and licensing fees from qualifying patents, capital gains from qualifying patent sales, and income from products that directly use qualifying patents (if the IP contribution is quantifiable); (3) Nexus approach (OECD BEPS compliance): the Swiss IP Box was reformed in 2020 (TRAF — Tax Reform and AHV Financing Act, effective January 1, 2020) to comply with the OECD's modified nexus approach under BEPS Action Plan 5. The key requirement: the IP Box benefit is proportional to the qualifying R&D expenditure incurred in Switzerland relative to total R&D expenditure. Companies must perform genuine R&D in Switzerland to claim full IP Box benefits; (4) Tax rate: cantons can allow a deduction of up to 90% of qualifying IP income, reducing the effective cantonal tax rate to maximum 10% of the standard cantonal rate. In low-tax cantons (Zug, Nidwalden, Schwyz), the effective combined federal + cantonal rate on IP Box income can be as low as 7.5–10%; (5) Substance requirement: a 'brass plate' IP holding company in Switzerland that acquires patents but performs no Swiss R&D cannot claim full IP Box benefits. The IP Box is designed for genuine Swiss R&D operations, not for tax arbitrage alone. Compare: Ireland's Knowledge Development Box (6.25% tax), Netherlands Innovation Box (9% tax), UK Patent Box (10% tax) — all have similar nexus requirements under BEPS Action Plan 5.

No. Switzerland, as an EPC (European Patent Convention) contracting state, applies Article 54 EPC — which requires absolute novelty for patentability. Any public disclosure of the invention before the patent application's filing date (or priority date, if priority is claimed) constitutes prior art and defeats novelty. This applies to: the inventor's own prior publications (journal articles, conference presentations, preprints); product demonstrations, trade show presentations, or press releases; patent applications previously filed but published before the priority date; and any other public disclosure worldwide. There is a very narrow exception under Article 55 EPC for disclosures made at officially recognized international exhibitions listed by the Bureau International des Expositions (BIE) — but this exception does NOT apply to scientific conferences, trade shows (not on the BIE list), investor presentations, or product launches. For US-based inventors: the US AIA § 102(b)(1)(A) provides a 12-month grace period for the inventor's own disclosures before a US patent application. This US grace period does NOT protect the Swiss/European patent application — if you disclosed your invention and filed the US application within 12 months, you preserved US rights but lost Swiss and European patent rights (assuming you had not also filed an EP or PCT application before the disclosure). The practical rule: file your patent application (at minimum a PCT or EP application) before any public disclosure to preserve Swiss patent rights. If you are a US startup that has already disclosed publicly and want US-only protection, file in the US within 12 months; if you want Swiss/European protection, it may already be too late.

A Swiss supplementary protection certificate (Ergänzendes Schutzzertifikat / Certificat complémentaire de protection — SPC) extends the effective term of a Swiss or EP-validated-in-Switzerland patent covering a pharmaceutical product or plant protection product. The extension compensates for the time spent on regulatory approval (Swissmedic authorization) before the product could be commercialized. Swiss SPC mechanics: (1) Eligibility: the product must be a pharmaceutical (drug) or plant protection product (pesticide/herbicide); the patent must have been filed at IPI or validated at IPI; the product must have received a Swissmedic marketing authorization; the SPC application must be filed at IPI within 6 months of the Swiss marketing authorization date; (2) Duration: the SPC term = (Swiss marketing authorization date − filing date of the basic patent) − 5 years. Maximum SPC term: 5 years. The maximum protected period (basic patent + SPC) cannot exceed 15 years from the first Swissmedic marketing authorization; (3) Pediatric extension: Swiss SPCs can receive a 6-month extension if the SPC holder conducts pediatric clinical studies under the terms of a Swissmedic pediatric investigation plan; (4) Independence from EU SPCs: Switzerland's SPC regime is legally independent from the EU SPC Regulation (Regulation 469/2009). The Swiss SPC term is based on Swissmedic authorization (not EMA authorization) and calculated under Swiss PatG Art. 140a–140q. If Swissmedic grants approval earlier than the EMA, the Swiss SPC will be shorter than the EU SPC; if later, it will be longer. Pharma companies must calculate Swiss SPCs separately and file timely SPC applications at IPI.

Yes — software can be patented in Switzerland through an EP patent validated at IPI, subject to the technical character requirement. Switzerland follows EPC Article 52(2)(c), which excludes 'programs for computers' from patentability 'as such.' The 'as such' limitation means that software with technical character — software that achieves a technical effect beyond the normal physical effects of running software on hardware — can be patented. IPI and the Swiss Federal Patent Court apply the EPO's approach to software patentability, which is more permissive than the post-Alice USPTO standard. Specifically, software inventions that would be rejected under Alice/Mayo at the USPTO as directed to an 'abstract idea' without an 'inventive concept' may still be patentable in Switzerland if they achieve a technical effect. Examples of software that is patentable in Switzerland (via EP route): industrial control software for CNC machines, robotics, or automation (Switzerland's precision engineering strength); medical device software (Ypsomed insulin pumps, Sonova hearing aid signal processing); telecommunications protocols; embedded software for automotive or aerospace systems; AI/ML applied to specific technical applications (real-time image processing for medical diagnosis, adaptive control systems). Software that CANNOT be patented in Switzerland: pure algorithms without technical application; business methods implemented purely in software; mental acts; games or entertainment software without a technical problem being solved. For Swiss startups building software in technically intensive areas (precision engineering, medtech, fintech infrastructure), the EP-to-Switzerland route offers a more favorable patent landscape than direct US filing.